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Evaluation of GWAS candidate
susceptibility loci for uterine
leiomyoma in the multi-ethnic NIEHS
uterine ﬁbroid study
Brahim Aissani 1*, Kui Zhang2 and Howard Wiener 1
1 Department of Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, USA,
2 Department of Biostatistics, University of Alabama at Birmingham School of Public Health, Birmingham, AL, USA
We evaluated the association of 56 candidate SNPs identiﬁed in two published
genome-wide association studies (GWAS) of uterine leiomyoma (UL), or ﬁbroids, with
the risk and tumor size in the multi-ethnic uterine ﬁbroid study (NIEHS-UFS). The
selected SNPs were genotyped in 916 premenopausal women of African American
(AA) and European American (EA) descents and their association with the outcomes
was evaluated in race-stratiﬁed models and in meta-analysis of risk in NIEHS-UFS
and discovery and replication GWAS in the Japanese population. We report moderate
associations of variant rs4954368 in THSD7B (thrombospondin, type I, domain
containing 7B) with tumor size in pooled analysis of AA and EA samples (P = 0.004),
and at TNRC6B (trinucleotide repeat containing 6B) variants rs138039 and rs139909
in EA (P = 0.001 and 0.008, respectively). The most signiﬁcant associations with risk
in meta-analysis were observed at TNRC6B variants rs739182 (P = 3.7 × 10−10) and
rs2072858 (P = 1.1 × 10−9) and were stronger than those reported in the discovery
GWAS (P = 2.01 × 10−8 and 2.58 × 10−8, respectively). The present study failed
to replicate the associations reported for CCDC57 and FASN in a discovery GWAS
in populations of European descent. Consistent with previous replication studies in
the Right From the Start Study (RFTS) and the BioVU DNA repository, we provide
independent evidence for association of TNRC6B with both risk and size of UL. The
present study is the ﬁrst to report a replicated association of THSD7B with UL, albeit
with tumor size and not with risk.
Keywords: uterine ﬁbroids, tumor size, thrombospondin, extracellular matrix, meta-analysis, genetic association,
African American, reproductive medicine
Introduction
Uterine leiomyoma (UL), or ﬁbroids, are common hormone-dependent tumors that arise in the
smooth muscle cells of the uterus. These tumors develop in>75% of North American women over
the reproductive age and become clinically apparent in about one-third (Cramer and Patel, 1990).
Although benign, UL cause signiﬁcant gynecologic morbidities includingmenorrhagia, pelvic pain,
urinary incontinence, infertility, and pregnancy complications (Stewart, 2001; Walker and Stewart,
2005). Uterine ﬁbroids are the primary indication for hysterectomy, with an incidence rate of 5.5
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per 1000 women in the United States and accounting for about
$9.4 billion of public health burden (Farquhar and Steiner, 2002).
Estrogen and progesterone are believed to promote the
growth of these tumors and long-term unopposed estrogens
are associated with risk (Andersen, 1996). Factors inﬂuencing
gonadal steroid metabolisms, such as obesity, diet, or exercise
show apparent association with risk (Schwartz et al., 2000). Age
(increasing risk with increasing premenopausal age), menopause
(risk decreases with menopause), and African American (AA)
ethnicity (higher risk compared with that of non-Hispanic
Whites), which was originally tested in NIEHS-UFS (National
Institute of Environmental Health Sciences-Uterine Fibroid
Study) (Baird et al., 2003) are established risk factors. The basis
for the higher prevalence among African Americans is not well-
understood. The genetic contribution to this ethnic disparity was
investigated in admixture-based genome-wide scans of the AA
population in BWHS (Black Women’s Health Study) (Wise et al.,
2012) and recently in NIEHS-UFS (Zhang et al., 2015). Both the
BWHS (Wise et al., 2012) and NIEHS-UFS found a decreased
mean percentage of European ancestry in UL cases compared
to controls. The negative correlation between European ancestry
and UL prevalence suggests that genetic factors may explain the
diﬀerent prevalence between AA and European American (EA)
women.
Genetic predisposition to UL was evidenced in early familial
aggregation studies (Vikhlyaeva et al., 1995; Sato et al., 2002).
Nonetheless, no convergent views on a potential mechanism
of pathogenesis have emerged from the genome linkage scans
and genome-wide association studies (GWAS) reported to date
(Gross et al., 2004; Cha et al., 2011; Eggert et al., 2012; Wise et al.,
2012). These GWA studies pointed to TNRC6B (trinucleotide
repeat containing 6B) and BET1L (Bet1 golgi vesicularmembrane
traﬃcking protein-like) as the most signiﬁcant candidate genes
in the Japanese population (Cha et al., 2011) and to FASN (fatty
acid synthase) and the nearby CCDC57 (coiled-coil domain
containing 57) gene in the European American population of
the WGHS (Women Genome Health study) (Eggert et al., 2012)
and Australian populations. Furthermore, genetic association
studies of UL in European American women enrolled in the
Right From The Start (RFTS) cohort and the Biorepository at
Vanderbilt University (BioVU) study reported replications of the
associations with BET1L and TNRC6B (Edwards et al., 2013a,b).
Recently, in an independent follow-up study to published linkage
(Eggert et al., 2012) and admixture (Wise et al., 2012) signals
for UL, we reported association data in NIEHS-UFS implicating
variants in genes encoding components of the extracellular
matrix (ECM) (Aissani et al., 2014), consistent with the current
paradigm for altered ECM in UL pathogenesis.
Whole genome sequencing of tumors have identiﬁed several
genes involved in UL pathology (Makinen et al., 2011; Mehine
et al., 2013) and cytogenetic analyses detected recurrent
chromosomal aberrations like those aﬀecting the high mobility
group AT-hook 2 (HMGA2) gene on chromosome 12 in band
q14.3 in tumorigenesis (Heim et al., 1988; Turc-Carel et al., 1988).
In contrast to these somatic mutations, germline mutations
aﬀecting highly conserved amino acids have been reported for the
fumarate hydratase-encoding gene (FH) on chromosome 1q43 in
tumor syndromes (Alam et al., 2001; Tomlinson et al., 2002) but
only in rare cases of non-syndromic UL (Barker et al., 2002; Kiuru
et al., 2002).
Replicating GWAS candidate SNPs in independent studies
of populations with diﬀerent ancestry, especially in the high-
risk African American population, is an important undertaking
toward validation of the association results reported in discovery
GWAS. Another motivation for conducting the present study
is the lack of shared candidate SNPs between the two available
GWAS. In the present study, we sampled 916 clinically
ascertained premenopausal women participants in the multi-
ethnic NIEHS-UFS to evaluate the association of candidate
SNPs (single nucleotide polymorphisms) from GWA studies
conducted in the Japanese (JPN), EA, and Australian (AUS)
populations, as well as a few SNPs in or nearby candidate genes,
with the risk of UL and tumor size. We report double-sided p-
values uncorrected for multiple testing from meta-analyses and
from race-stratiﬁed analyses for the two predominant AA (393
cases and 132 controls) and EA (195 cases and 196 controls)
ethnic groups from logistic regression models with or without
adjustment for covariates.
Materials and Methods
Study Population
The characteristics of the study population were reported in
previous studies (Aissani et al., 2013, 2014). Brieﬂy, women aged
35–51 years, were randomly selected from a computerized list of
members of a prepaid urban health plan for enrollment in the
NIEHS-UFS (Baird et al., 2003). Self-administered questionnaires
were used to collect demographic data. Reproductive and
gynecologic history data were collected during a telephone
interview. About 92% of the study population was self-identiﬁed
as AA or non-Hispanic EA. Among the premenopausal women
enrolled in the study and who had ultrasound examinations
(n = 1119), 1045 (93%) had available DNA specimens and
were of African American (n = 574), non-Hispanic European
American (394) or other (n = 77) ethnicity. The NIEHS-UFS
and the present sub-study were approved by the Human Subject’s
Review boards at the NIEHS, GeorgeWashington University and
University of Alabama at Birmingham, respectively. Participants
to NIEHS-UFS were fully informed and were enrolled only after
full written consents were obtained.
For meta-analysis, model estimates were available only from
the GWAS in the Japanese population (Cha et al., 2011). This
GWAS sampled 1607 individuals clinically diagnosed with UL
and 1328 individual controls for the discovery study, and 3466
clinically diagnosed UL cases 3245 individual controls for the
replication study. The GWAS obtained written patient consents
in accordance with the Ethical Committee at each of The Institute
of Medical Science of the University of Tokyo and the Center for
Genomic Medicine of RIKEN.
Covariates
Covariates included age, age at menarche, parity (pregnancies
after age 25; earlier births were not signiﬁcantly related to ﬁbroid
development in the NIEHS-UFS cohort (Dunson and Baird,
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2002; Baird and Dunson, 2003), body mass index (BMI), and
physical activity.
Ascertainment
Fibroid status was assessed by ultrasonography at baseline or by
medical record review in 80 and 90% of AA and EA participants,
respectively. For the study participants who had recent pelvic
ultrasound examinations, the radiology records were examined
for the presence of ﬁbroids. The remaining participants were
asked to have a pelvic ultrasound examination at a primary
care site. If neither ultrasounds nor medical record reviews
could be conducted, the concerned participants were excluded
from the present study. Clinical examinations consisted of
both transabdominal and transvaginal ultrasonographies. The
abdominal portion evaluated ﬁbroid changes arising from the
upper uterus that could be missed by the transvaginal approach
alone. Tumor size was classiﬁed in three categories (Small,
Medium, and Large) measured by the diameter of the tumors (S
≤ 2 cm, 2 cm<M< 4 cm, L≥ 4 cm). For participants diagnosed
with multiple tumors, the largest tumor determined the size
category.
No clinical information on the size of ﬁbroids was available
in the GWAS sample used in meta-analysis. Compared with
the reported family history among cases (21.03 and 16.56% for
the discovery and replication samples, respectively), only 5.11
and 1.94% of the controls in the discovery and replication sets,
respectively, reported family history of UL (Cha et al., 2011).
SNP Selection and Typing
Illumina iSelect assay (Illumina Inc., San Diego, CA) was used
to type a total of 63 SNPs selected among the most signiﬁcantly
associated SNPs in GWAS. We also included additional SNPs
in associated genes or genes adjacent to them, as well as a
small number of SNPs in the candidate HMGA2. Reliability in
typing data was assessed by inclusion of blind intra- and inter-
plate duplicates representative of each of the study population
groups. For accurate assessment of African descent, we included
a set of 25 unrelated Yoruban (YRI) samples. A total of 2682
SNPs (from an extended set of 4363 SNPs typed in a previous
study and also that included 147 ancestry informative markers)
that were common to our data and to the majority of the
HapMap III reference populations was used to assess ethnic
membership of quality control samples. About 35% of the SNPs
were from chromosome 1q43; the remaining SNPs have genome-
wide distribution (Aissani et al., 2014). All SNPs in the extended
set were selected to have a minor allele frequency (MAF) of at
least 5% and most of them are inter-population tagging SNPs
relevant to the ethnic backgrounds of the NIEHS-UFS study
populations (Aissani et al., 2013).
Principal component analysis was used to assess the Japanese
ethnicity of the case and control individuals sampled for the
GWAS (Cha et al., 2011). The control individuals studied in
the discovery and replication GWAS were older than the cases
(mean ages 42.5 vs. 48.9 years and 45.2 vs. 62.3 years in
discovery and replication sets, respectively). This study design is
important to keep downward the rate of misclassiﬁcation, which
can be substantial in case and control studies where controls are
not clinically ascertained. The participants to NIEHS-UFS were
all ≥35 years of age and about two-thirds were ≥40 years of age.
Statistical Analysis
Quality Control
SNP calls were checked for adherence to Hardy–Weinberg
equilibrium (HWE) in each of the aﬀection status and population
stratum, and SNPs deviating (p < 0.01) from HWE in UL-free
controls were excluded.
Analytical Design
Association of SNPs with risk of UL and tumor size was evaluated
separately in each population stratum using dichotomous and
polytomous logistic regression modeling, respectively, in SAS
(SAS, Cary, NC), and in meta-analyses by ﬁtting random
eﬀect models to the data in the metafor R package (http://
www.jstatsoft.org/v36/i03/) (Viechtbauer, 2010). Heterogeneity
between studies was assessed by the Cochran’s Q-test that is
part of DerSimonian-Laird estimator in the pooling method
(DerSimonian and Laird, 1986). Because the discovery GWAS
data were derived from models with no adjustments for the
covariates, for comparisons, we report data from both adjusted
and unadjusted models in NIEHS-UFS and from unadjusted
models in the meta-analysis of NIEHS-UFS and Japanese GWAS.
Previous studies in NIEHS-UFS have assessed the levels of
the ordinal covariates that inﬂuenced or modiﬁed the risk of UL
(Baird et al., 1998, 2007; Baird and Dunson, 2003); we therefore
modeled these covariates accordingly. Speciﬁcally, we modeled
age as a continuous variable and BMI as an ordinal variable
(based on categories <25, 25–29.99, 30–34.99, 35+). The other
covariates were age of menarche modeled as a dichotomous
variable (age <11 years vs. other ages), exercise as a 4-level
ordinal variable (lower third, middle third, next sixth, top sixth
as described (Baird et al., 2007) and parity deﬁned as having or
not having given birth at age 25 and older (binary variable).
The association of SNP genotypes with UL outcomes
was tested in principal component analysis (PCA)-deﬁned
groups assuming additive genetic eﬀects as described (Aissani
et al., 2013). For the polytomous models, the assumption for
proportional odds in both or in either AA or EA study population
was checked and reported if not met. UL was modeled as a
dichotomous outcome (case-control design comparing UL-free
category to the combination of tumor size categories S, M, and
L) or as a polytomous outcome comparing UL size categories (S
vs.M and L and S andM vs. L).
SNP tests that passed Bonferroni-corrected signiﬁcance
thresholds, which were p = 0.05/56= 9×10−4 formultiple testing
of 56 quality control-ﬁltered SNPs in NIEHS-UFS and genome-
wide signiﬁcance p = 10−7 in meta-analysis of NIEHS-UFS and
discovery GWAS, were deemed to be statistically signiﬁcant.
Results
Characteristics of the participants available for testing the genetic
association with the risk of UL (case-control design) and tumor
size (case-only design) were reported in a previous study (Aissani
et al., 2013, 2014). Except for a unique individual of European
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descent, typing was achieved in the entire study population
(n = 1045). The call rate was >98% in about 92% of sampled
individuals. Among the 1045 typed samples, 42 (4.0%) with call
rates<90%were excluded from the analysis; this yielded a total of
1003 samples for analysis. The overall concordance rate between
duplicates was 99.6%, implying that a false discovery due to
typing errors is unlikely. Discriminant analysis corrected ethnic
group inference for several individuals who self-identiﬁed as
“other populations” to either EA or AA ancestry (Supplementary
Figure 1). Sixteen individuals who self-identiﬁed as African
American (AA) and one individual as a non-Hispanic European
American (EA) clustered more closely with the Yoruban African
population (YRI). This observation prompted the exclusion of
this subset of 17 individuals, resulting in a total of 986 individuals
(525 AA, 391 EA, and 70 other) available for analysis.
Of the 63 assayed SNPs, 56 passed the QC ﬁlters including
adherence to HWE in the control groups. Tables 1, 2 display
the results of association with the risk and tumor size outcomes,
respectively, for the most signiﬁcant (Bonferroni-uncorrected
P ≤ 0.05) SNPs in any of the tested models. Race-stratiﬁed
analyses and meta-analyses were restricted to the two largest
ethnic groups AA and EA. To allow comparisons with the
discovery GWAS, which were not adjusted for the covariates
modeled in the present study, we report results frommodels with
or without adjustment for covariates (Supplementary Tables S1,
S2). The results showed no signiﬁcant diﬀerences between the
adjusted and unadjusted models.
Race-stratiﬁed analyses of risk showed moderate associations
(P < 0.05) with 6 SNPs, one in each of chromosomes 8,
11, and 12, and 3 on chromosome 22 (Table 1). The most
signiﬁcant association (P = 0.005) occurred in the AA group
at rs1481046 located about 15 Kb upstream of a long-non-coding
RNA (LOC101926892) of uncharacterized function. Among the
associated SNPs, three locate to or near previously replicated
BETL1 and TNRC6B genes (Edwards et al., 2013b). The intronic
SNP rs11601352 in PSMD13 (proteasome 26S subunit, non-
ATPase, 13) is located about 40Kb from the replicated candidate
BET1L. The moderate association with this SNP was observed
only in the AA group and in meta-analysis (P = 0.042),
whereas the association with the two other SNPs, rs6001794, and
rs11089974, in TNRC6B was observed in the EA group but not
in the meta-analysis. The two other associated SNPs in the AA
group, rs2270451 (P = 0.024) and rs2301523 (P = 0.039), are
located in the 2-Kb upstream sequence of GPR19 (G protein-
coupled receptor 19) and within the non-protein coding RNA
MIAT (myocardial infarction associated transcript), respectively.
Two TNRC6B intronic SNPs, rs739182, and rs2072858, showed
moderate associations (P = 0.030 and P = 0.025, respectively)
but only in meta-analyses; these SNPs are in strong linkage
disequilibrium (LD) in EA (r2 = 0.95; Supplementary Table S4)
and in moderate LD in AA (r2 = 0.58; Supplementary Table S5).
Association with tumor size was tested in case-only designs
using proportional odds models and assuming an additive
genetic model with adjustments for covariates. No variants that
associated with risk also associate with tumor size; however,
SNPs in TNRC6B other than those aﬀecting risk inﬂuenced
signiﬁcantly (P = 0.001 at rs138039 and P = 0.008 at rs139909)
tumor size in EA (Table 2). Examination of the LD pattern in
TNRC6B showed that these two SNPs are in LD with each other
both in EA (r2 = 0.74) and AA (r2 = 0.76) but not with any
other tested TNRC6B SNP (r2 < 0.05) in AA (Supplementary
Table S5) or in EA (r2 < 0.35) (Supplementary Table S4).
Variant rs12423095 in HMGA2 showed a moderate
association with tumor size in AA only although no signiﬁcant
heterogeneity was observed between AA and EA (Supplementary
Table S2), possibly indicating a spurious association due to
the low minor allele frequency at this SNP. Consistent with
these data, rs12423095 showed weak or no LD (r2 < 0.15)
with the other tested HMGA2 SNPs in both study groups.
The sole association with tumor size observed separately in
AA (P = 0.035) and EA (P = 0.046), and in meta-analysis
(P = 0.004) was with the intronic variant rs4954368 in THSD7B
(thrombospondin, type I, domain containing 7B gene) (Table 2
and Table S2). Of note, given that none of the signiﬁcantly
associated SNPs failed to meet the assumption for proportional
odds, these results imply single OR for the contrasted ordinal
outcomes.
We re-evaluated the association of the full set of 56 SNPs
with risk in meta-analyses of NIEHS-UFS (n = 916) and the
discovery (n = 3035) and replication (n = 6711) GWAS
in the Japanese population (Cha et al., 2011). The results of
the meta-analyses showed signiﬁcant associations (P < 1.3 ×
10−7) with 5 of the 8 tested SNPs in TNRC6B and a moderate
association at the candidate PSMD13/BET1L region (rs11601352,
P = 0.0047) (Table 3). In particular, TNRC6B variants rs739182
(P = 3.7 × 10−10) and rs2072858 (P = 1.1 × 10−9)
showed stronger associations than in the discovery GWAS (P =
2.01 × 10−8 and 2.58 × 10−8, respectively). No association was
observed at the TNRC6B variants rs138039 and rs139909 that
associated moderately with tumor size in the EA group (Table 2).
Examination of the minor allele frequency (MAF) at these two
SNPs showed higher MAFs in EA compared to AA, and opposite
minor and major alleles in the Japanese population (Table S3).
Moderate heterogeneities between the studies were observed
at three gene loci including PSMD13/BET1L but not at the
signiﬁcantly associated TNRC6B or at the moderately associated
CCDC57. Of note, the variant rs6502051 inCCDC57, whichmaps
3 Kb away from the top candidate FASN in WGHS (Eggert
et al., 2012) was not reported in the Japanese GWAS. This SNP
showed weak LD with our tested SNPs in FASN in EA and
AA (Supplementary Tables S4, S5). The slightly diﬀerent results
obtained for this SNP (P = 0.13 in Table S1 and P = 0.029 in
Table 3) stem from the use of models with (Table 1 and Table S1)
and without (Table 3) adjustment for covariates.
Strong heterogeneity (P = 3.2× 10−4) across the studies was
also observed at the THSD7B variant rs4954368 in the test of
association with the risk outcome (Table S3).
Discussion
In the present NIEHS-UFS, we attempted replications of GWAS
ﬁndings for uterine ﬁbroids in the Japanese population and
reported moderate and signiﬁcant associations in race-stratiﬁed
analyses and in meta-analyses depending on the SNP and
Frontiers in Genetics | www.frontiersin.org 4 July 2015 | Volume 6 | Article 241
Aissani et al. The genetic determinants of uterine ﬁbroids
TA
B
LE
1
|A
ss
o
ci
at
io
n
o
f
ca
nd
id
at
e
S
N
P
s
a
w
it
h
ri
sk
o
f
ut
er
in
e
ﬁ
b
ro
id
s
in
th
e
N
IE
H
S
ut
er
in
e
ﬁ
b
ro
id
st
ud
y.
S
N
P
A
lle
le
b
A
1
fr
eq
ue
nc
y
C
hr
d
P
o
si
ti
o
n,
b
p
G
en
e/
g
en
e
re
g
io
n
Lo
g
is
ti
c
re
g
re
ss
io
ne
M
et
a-
an
al
ys
is
A
1
A
2
N
IE
H
S
-U
FS
c
E
A
(n
=
39
1)
A
A
(n
=
52
5)
E
A
+
A
A
(n
=
91
6)
(E
A
)
(A
A
)
A
d
ju
st
ed
U
n-
ad
ju
st
ed
A
d
ju
st
ed
f
U
n-
ad
ju
st
ed
P
P
-h
et
g
O
R
f
P
P
O
R
P
P
rs
14
81
04
6
G
T
0.
39
7
0.
36
0
8
71
,3
71
,9
02
LO
C
h
0.
90
4.
9E
-0
1
7.
7E
-0
1
0.
65
4.
9E
-0
3
2.
2E
-0
2
1.
5E
-0
1
1.
2E
-0
1
rs
11
60
13
52
A
G
0.
04
2
0.
01
6
11
24
9,
10
5
P
S
M
D
13
i
0.
62
2.
3E
-0
1
3.
9E
-0
1
0.
35
4.
2E
-0
2
4.
2E
-0
2
4.
2E
-0
2
9.
9E
-0
1
rs
22
70
45
1
C
T
0.
12
4
0.
03
5
12
12
,8
49
,8
26
G
P
R
19
j
1.
50
1.
0E
-0
1
8.
8E
-0
2
3.
51
2.
4E
-0
2
4.
6E
-0
2
2.
2E
-0
2
5.
4E
-0
1
rs
23
01
52
3
A
G
0.
13
0
0.
19
7
22
27
,0
62
,6
69
M
IA
T
0.
90
6.
4E
-0
1
8.
6E
-0
1
1.
49
3.
9E
-0
2
5.
9E
-0
2
6.
3E
-0
1
6.
4E
-0
2
rs
60
01
79
4
T
G
0.
21
2
0.
21
9
22
40
,5
29
,4
15
TN
R
C
6B
0.
66
3.
4E
-0
2
3.
3E
-0
2
1.
05
7.
8E
-0
1
8.
4E
-0
1
1.
8E
-0
1
4.
3E
-0
1
rs
11
08
99
74
T
C
0.
21
6
0.
20
7
22
40
,5
43
,6
08
TN
R
C
6B
0.
67
4.
4E
-0
2
5.
9E
-0
2
1.
07
7.
2E
-0
1
9.
4E
-0
1
3.
5E
-0
1
4.
0E
-0
1
rs
73
91
82
T
G
0.
33
8
0.
12
2
22
40
,6
15
,2
76
TN
R
C
6B
0.
76
8.
8E
-0
2
1.
6E
-0
1
0.
76
2.
4E
-0
1
2.
7E
-0
1
3.
0E
-0
2
5.
7E
-0
1
rs
20
72
85
8
C
T
0.
34
5
0.
15
9
22
40
,7
08
,6
79
TN
R
C
6B
1.
32
8.
4E
-0
2
1.
3E
-0
1
1.
14
4.
9E
-0
1
5.
8E
-0
1
2.
5E
-0
2
9.
7E
-0
1
a
C
an
di
da
te
si
ng
le
nu
cl
eo
tid
e
po
ly
m
or
ph
is
m
s
(S
N
P
s)
th
at
pa
ss
ed
th
e
th
re
sh
ol
d
of
si
gn
iﬁ
ca
nc
e
in
a
ge
no
m
e-
w
id
e
as
so
ci
at
io
n
st
ud
y
(G
W
A
S
)o
fu
te
rin
e
le
io
m
yo
m
a
in
th
e
Ja
pa
ne
se
po
pu
la
tio
n
(C
ha
et
al
.,
20
11
).
b
A
1,
A
lte
rn
at
e
al
le
le
;A
2,
re
fe
re
nc
e
al
le
le
.
c
N
at
io
na
lI
ns
tit
ut
e
of
En
vi
ro
nm
en
ta
lH
ea
lth
S
ci
en
ce
ut
er
in
e
ﬁb
ro
id
st
ud
y
(N
IE
H
S
-U
FS
)i
n
A
fri
ca
n
A
m
er
ic
an
(A
A
)a
nd
Eu
ro
pe
an
A
m
er
ic
an
(E
A
)p
op
ul
at
io
ns
.
d
C
hr
om
os
om
e.
e
Lo
gi
st
ic
re
gr
es
si
on
an
al
ys
is
as
su
m
in
g
an
ad
di
tiv
e
ge
ne
tic
m
od
el
.
f O
dd
s
ra
tio
s
(O
R
)f
ro
m
m
od
el
s
ad
ju
st
ed
fo
r
ag
e,
ag
e
at
m
en
ar
ch
e,
pa
rit
y
af
te
r
ag
e
25
,b
od
y
m
as
s
in
de
x,
an
d
ph
ys
ic
al
ac
tiv
ity
.
g
p-
Va
lu
e
fo
r
he
te
ro
ge
ne
ity
(P
-h
et
)a
cr
os
s
sa
m
pl
es
.
h
A
bo
ut
15
K
b
up
st
re
am
of
lo
ng
-n
on
-c
od
in
g
R
N
A
LO
C
10
19
26
89
2.
i In
tr
on
ic
S
N
P
in
P
S
M
D
13
(p
ro
te
as
om
e
26
S
su
bu
ni
t,
no
n-
AT
P
as
e,
13
)l
oc
at
ed
ab
ou
t4
0
K
b
fro
m
ca
nd
id
at
e
B
ET
1L
(B
et
1
go
lg
iv
es
ic
ul
ar
m
em
br
an
e
tr
af
ﬁc
ki
ng
pr
ot
ei
n-
lik
e)
.
j S
N
P
in
th
e
2-
K
b
up
st
re
am
se
qu
en
ce
of
G
P
R
19
(G
pr
ot
ei
n-
co
up
le
d
re
ce
pt
or
19
).
M
IA
T
(m
yo
ca
rd
ia
li
nf
ar
ct
io
n
as
so
ci
at
ed
tr
an
sc
rip
t);
TN
R
C
6B
(tr
in
uc
le
ot
id
e
re
pe
at
co
nt
ai
ni
ng
6B
).
Frontiers in Genetics | www.frontiersin.org 5 July 2015 | Volume 6 | Article 241
Aissani et al. The genetic determinants of uterine ﬁbroids
TABLE 2 | Association of candidate SNPs a with the size of uterine ﬁbroids in NIEHS uterine ﬁbroid study.
SNP Alleleb A1 frequency Chrd Position, bp Gene/gene region Logistic regressione Meta-analysis
A1 A2 NIEHS-UFSc EA (n = 195) AA (n = 393) EA + AA (n = 588)
(EA) (AA) ORf P OR P P P-hetg
rs4503307 C T 0.041 0.237 1 80,641,525 intergenic 1.15 7.8E-01 1.50 2.1E-02 1.3E-01 2.4E-01
rs4954368 C T 0.303 0.383 2 137,757,933 THSD7B 1.51 4.6E-02 1.34 3.5E-02 4.3E-03 6.6E-01
rs12423095 C T 0.018 0.047 12 66,291,232 HMGA2 0.89 8.6E-01 1.96 3.9E-02 4.7E-01 9.9E-01
rs2226994 G A 0.351 0.489 16 13,664,942 LOCh 1.67 1.5E-02 1.00 9.8E-01 4.0E-01 4.3E-02
rs138039 A G 0.369 0.109 22 40,621,288 TNRC6B 1.96 1.3E-03 0.88 5.8E-01 2.1E-01 1.6E-01
rs139909 C T 0.313 0.084 22 40,697,581 TNRC6B 1.73 7.9E-03 0.96 8.7E-01 8.5E-02 2.6E-01
aCandidate single nucleotide polymorphisms (SNPs) that passed the threshold of signiﬁcance in a genome-wide association study (GWAS) of uterine leiomyoma (UL) in the Japanese
population (Cha et al., 2011), with exception to rs12423095, which was selected from UL candidate gene HMGA2 (high mobility group AT-hook 2).
bA1, Alternate allele; A2, reference allele.
cNational Institute of Environmental Health Science uterine ﬁbroid study (NIEHS-UFS) in African American (AA) and European American (EA) populations.
dChromosome.
eProportional odds models from logistic regression analysis.
fOdds ratios (OR) from logistic regression models adjusted for age, age at menarche, parity after age 25, body mass index, and physical activity.
gP-het: P-value for heterogeneity across samples.
hLOC101927287; THSD7B (thrombospondin, type I, domain containing 7B) TNRC6B (trinucleotide repeat containing 6B).
TABLE 3 | Meta-analysis of risk of uterine leiomyoma among North American and Japanese women.
SNPa Chrb Position, bp allelec A1 allele frequencyd Gene/gene
region
Meta-analysis
A1 A2 EA AA JPN Beta SEe P P-hetf
(n = 525) (n = 391) (n = 9746)
rs991964 2 59,282,591 A G 0.458 0.165 0.329 LINC01122 0.162 0.066 1.5× 10−2 0.044
rs11601352 11 249,105 A G 0.042 0.016 0.055 PSMD13 0.384 0.136 4.7× 10−3 0.067
rs2172873 12 103,125,690 T C 0.060 0.322 0.203 PAH/IGF1 0.165 0.065 1.2× 10−2 0.100
rs2226994 16 13,664,942 A G 0.367 0.491 0.772 LOC101927287 0.125 0.063 4.7× 10−2 0.062
rs6502051 17 80,059,332 A C 0.481 0.383 CCDC57 0.228 0.104 2.9× 10−2 0.300
rs6001794 22 40,529,415 T G 0.212 0.219 0.358 TNRC6B −0.206 0.039 1.3× 10−7 0.290
rs11089974 22 40,543,608 T C 0.216 0.207 0.365 TNRC6B −0.185 0.032 7.5× 10−9 0.360
rs739182 22 40,615,276 T G 0.338 0.122 0.488 TNRC6B −0.166 0.027 3.7× 10−10 0.530
rs12484776 22 40,652,873 G A 0.208 0.089 0.381 TNRC6B −0.204 0.030 5.7× 10−12 0.590
rs2072858 22 40,708,679 C T 0.345 0.159 0.489 TNRC6B −0.161 0.026 1.1× 10−9 0.630
aCandidate single nucleotide polymorphisms (SNPs) that passed the threshold of signiﬁcance in a genome-wide association study (GWAS) of uterine leiomyoma in the Japanese
population (Cha et al., 2011), with exception to the SNP in CCDC57 (coiled-coil domain containing 57 gene) which was selected along with other SNPs (Tables S1 and S2) from a
GWAS in European American and Australian populations of the Women’s Genome Health Study (WGHS) (Eggert et al., 2012). Note that because estimates of beta and SE from WGHS
were not available for the present study, only estimates obtained for the NIEHS-UFS African American (AA) and European American (EA) samples were used in meta-analysis.
bChromosome.
cA1, Alternate allele; A2, reference allele.
dAlternate allele (A1) frequency in AA, EA, and Japanese (JPN).
eBeta coefﬁcients (beta) and standard errors (SE) from meta-analyses using random-effect models. For consistency with the model used in the GWAS in JPN, beta and SE estimates
for the NIEHS-UFS samples were from unadjusted logistic regression models (Table 1 and Table S1).
f P-value for heterogeneity (P–het). LINC01122 (long intergenic non-protein coding RNA 1122); PSMD13 (proteasome 26S subunit, non-ATPase, 13) located about 40Kb from candidate
BET1L (Bet1 golgi vesicular membrane trafﬁcking protein-like); PAH (phenylalanine hydroxylase); IGF1 (Insuline-like growth factor 1); TNRC6B (trinucleotide repeat containing 6B).
outcome (risk or tumor size) under consideration. The most
striking results were replicated associations of several variants in
TNRC6Bwith either risk or tumor size. Based on the observed LD
patterns across the associated SNPs, our data suggest the presence
of two common TNRC6B haplotypes associated independently
with risk or size of UL. Our data in NIEHS-UFS are consistent
with the previous replication of TNRC6B SNP associations with
risk and tumor size among European Americans in the BioVu
and RFTS studies (Edwards et al., 2013a,b); however, diﬀerences
between the association results from these replication studies
were also observed. First, only few SNP associations could be
compared because RFST/BioVU studies were focused on the
three top GWAS genes (BET1L, TNRC6B, and near SLK genes)
whereas the NIEHS-UFS examined all genome-wide signiﬁcant
SNPs. Among the rare overlapping SNPs in these replication
studies TNRC6B rs12484776 was associated moderately with risk
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in RFTS and BioVu, and with increasing ﬁbroid volume in RFTS
whereas in NIEHS-UFS no association was observed with this
SNP. The association observed in the meta-analysis of NIEHS-
UFS and GWAS samples (Table 3) is solely explained by the
latter samples. Second, while none of these studies reported
evidence for TNRC6B rs139909 association with risk, association
with tumor size (OR=1.73; p = 0.008) was observed in the
EA group in our study, potentially suggesting decreased power
in the AA group that can be explained by the low MAF at
this SNP.
We also reported moderate associations of intronic variant
rs4954368 in THSD7B (thrombospondin, type I, domain
containing 7B) with tumor size in race-stratiﬁed analyses and
combined analyses of AA and EA in NIEHS-UFS but not in
meta-analysis of risk in NIEHS-UFS and prior GWAS samples.
The negative association with risk in the meta-analysis of the
two studies is not inconsistent with the results from the separate
studies, which showed no association in NIEHS-UFS and strong
heterogeneity (P = 1.8 × 10−5) in the reported meta-analysis
of the discovery and replication GWAS in the Japanese study
(Cha et al., 2011). The reported association of THSD7B with
tumor size may not be a spurious ﬁnding because (i) it was
observed in a case-only design, (ii) the strength and direction
of the association are similar in each study population, and
(iii) the EA and AA groups share the allele “C” associated with
tumor size.
A potential explanation to the observed association of
rs4954368 with risk in the discovery GWAS but only with tumor
size in NIEHS-UFS is the non-clinical ascertainment of the
controls in the discovery GWAS. Non-clinical ascertainment of
controls in cross-sectional studies of UL may be prone to high
misclassiﬁcation rates because women with small tumors are
likely to be asymptomatic and consequently might not draw
clinical attention. In the setting of high misclassiﬁcation rates
(large proportions of cases misclassiﬁed as controls), case and
control designs would also test an ordinal outcome (small tumors
vs. tumors with varying sizes). Thus, despite an appropriate and
robust design of the reported GWAS (controls older than cases),
misclassiﬁcations cannot be excluded. Alternatively, the negative
association of THSD7B with risk and positive association with
tumor size in NIEHS-UFS may reﬂect a pathogenic mechanism
whereby the tagged causal variant in THSD7B is a secondary
mutation rather than a driver mutation. Another possible
explanation is the level of circulating estrogen, which aﬀects the
production of thrombospondins and may diﬀer in NIEHS-UFS
and the GWAS.
THSD7B encodes a member of the thrombospondins (TSP)
which are potent inhibitors of angiogenesis and therefore may
be important in controlling tumor growth (Vallbo and Damber,
2005). TSPs are secreted by various kinds of cells including
endothelial and smooth muscle cells. These secreted molecules
aﬀect cell functions by modulating cell-matrix interactions. This
ﬁnding converges with those from our recent study in NIEHS-
UFS that implicated variants of encoded components of the
extra-cellular matrix (Aissani et al., 2014).
We also reported that the intronic variant rs138039 in
TNRC6B is associated with tumor size in EA with a signiﬁcance
level close to the Bonferroni-corrected threshold of P = 0.0009
and that the lower MAF in AA likely precluded detection of
the association. The association of tumor size with a diﬀerent
TNRC6B variant (rs12484776) in RFTS (Edwards et al., 2013a),
albeit moderately (P = 0.024), supports a candidate status for
this gene because the observed association with a diﬀerent variant
in the same gene in RFTS reduces the possibility of biased results
for rs138039 and rs139909 in NIEHS-UFS (not tested in RFTS).
Given that these associated variants most likely tag rather than
being the actual causal variant(s), cryptic diﬀerence in the pattern
of linkage disequilibrium between the EA samples in NIEHS-UFS
and RFTS or genetic heterogeneity (diﬀerent causal variants) may
explain the observed results.
We were not able to assess the replicated association with
the BET1L 3′UTR variant rs2280543 that was reported in RFTS
and BioVU; this variant did not pass the QC ﬁlter in our study.
Nonetheless, the GWAS discovery variant rs11601352 in the
adjacent PSMD13 gene was shown to associate moderately with
the risk of UL in AA and in meta-analysis in NIEHS-UFS (P =
0.042). The low frequency (MAF = 0.02) of the associated allele
“A” at this SNP site, as well as that at rs2280543 in EA in RFTS
and BioVU, precludes conclusive statements. Thus, validation
of this association in other study populations with higher MAF
is needed. Variant rs11601352 is not represented in the 1000
Genomes database and the highest MAF reported for this SNP in
the HapMap III database is in populations of Mexican ancestry
(MEX; MAF = 0.15), followed by Asian ancestries (China and
Japan) with a MAF of 5%.
The function of TNRC6B is not known; however, this gene
was highlighted as a candidate in GWAS for height (Estrada
et al., 2009) and for age-at-menarche (Guo et al., 2006), which
is a risk factor for UL (Marshall et al., 1997; Baird et al.,
2003; Wise et al., 2004). Although no association was observed
between TNRC6B variants and age-at-menarche in NIEHS-UFS
(unpublished data), validation of the reported association in
independent GWAS could imply that the encoded product of
TNRC6B functions in the causal pathway. Of potential relevance
to these independent replications of TNRC6B association with
UL, the expression of the TNRC6A paralog was reported to
be markedly dysregulated in large ﬁbroids compared to small
ﬁbroids (log2 fold change = −1.00, p = 0.0008) (Guo et al.,
2014). The TNRC6 paralogs encode members of the GW182
protein family that are essential components of the miRNA
pathway (Yao et al., 2012), which has been implicated in the
pathogenesis of uterine ﬁbroids (Marsh et al., 2008; Wei and
Soteropoulos, 2008).
We also reported a moderate association of the common
CCDC57 variant rs6502051 with protection against UL in the
AA group; however, the decreased level of signiﬁcance for this
SNP after controlling for the covariates suggested potential
confounding eﬀects. Furthermore, the negative association of
the other common SNPs in this gene as well as in the nearby
FASN with either outcome or study group remains unclear and
requires conﬁrmation in independent study populations. Finally,
several SNP associations including those reported for GPR19,
HMGA2, MIAT, PSMD13/BET1L and for other annotated or
non-annotated gene loci had either low minor allele frequencies,
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were observed only in unadjusted models or that the association
was lost or dropped signiﬁcantly in meta-analysis of EA and AA
or of EA, AA, and JPN samples.
The relevance of the encoded product of THSD7B, the sole
gene that consistently associated with tumor size in EA and
AA populations, to UL pathogenesis is not known. Very little is
known about the function of this gene; it encodes a member of
the thrombospondin family which are matricellular modulators
of cell function (Bornstein, 2001). Of note, another member
of the thrombospondin-encoding genes, THBS1 (alias TSP-1),
was reported to be down-regulated in uterine ﬁbroids (Behera
et al., 2007) and TSP-1 production has been shown to be
directly controlled by estrogens in estrogen receptor-positive
breast cancer cells (Hyder et al., 2009), suggesting that TSP-1 may
function in the estrogen receptor-positive UL cells as well. Thus,
the possibility that the product of THSD7B functions in the same
pathway as TSP-1 cannot be excluded.
In conclusion, the present work replicated the association
of TNRC6B with risk and size of UL consistent with the
ﬁrst reported replication of these associations in the RFTS
and BioVU studies. Of potential relevance to the pathogenesis
of UL, we reported an association of the thrombospondin-
encoding THSD7Bwith tumor size in both European and African
American populations.
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